Product Description
Mechanisms of Action: IL22 Antagonist
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Subcutaneous, Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: Eastern America
Company Founding Year: 1849
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Arthritis, Rheumatoid|Dermatitis, Atopic
Phase 1: Psoriasis|Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00563524 |
3199K2-1105 | P1 |
Completed |
Psoriasis |
2010-06-14 |
2024-08-24 |
||
NCT00434746 |
3199K1-1102 | P1 |
Completed |
Healthy Volunteers |
2008-02-01 |
2019-03-21 |
Treatments |
|
NCT00447681 |
3199K1-100 | P1 |
Completed |
Healthy Volunteers |
None |
2019-03-21 |
Treatments |
|
NCT01941537 |
JKR-0766 | P2 |
Completed |
Dermatitis, Atopic |
2016-02-01 |
2019-05-08 |
||
NCT00883896 |
3199K1-2001 | P2 |
Completed |
Arthritis, Rheumatoid |
2011-02-18 |
2022-10-22 |
||
JapicCTI-101247 |
JapicCTI-101247 | P2 |
Completed |
Arthritis, Rheumatoid |
2011-02-18 |
|||
2008-006936-37 |
2008-006936-37 | P2 |
Completed |
Arthritis, Rheumatoid |
2011-02-18 |
2022-03-13 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
03/25/2024 |
PubMed |
Interplay of cytokines in the pathophysiology of atopic dermatitis: insights from Murin models and human. |
|
12/16/2021 |
PubMed |
[Novel therapies in the treatment of atopic dermatitis]. |
|
12/13/2021 |
PubMed |
Safety and Danger Considerations of Novel Treatments for Atopic Dermatitis in Context of Primary Cutaneous Lymphomas. |